Dr. Fanale on Brentuximab Vedotin in High-Risk ALCL

Michelle A. Fanale, MD
Published: Wednesday, Jan 30, 2013

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma (ALCL).

In the phase II trial, patients with low-risk factors saw a 70% to 80% chance of being in remission for five years, compared to 15% to 20% of patients with higher risk factors. In the phase III trial, Fanale says, researchers look to compare CHOP chemotherapy to brentuximab vedotin + CHP in the frontline treatment of mature T-cell lymphomas and to enroll patients with high-risk disease. The goal remains to improve outcomes for high-risk patients by escalating chemotherapy or adding a targeted therapy.

Brentuximab vedotin is currently approved for Hodgkin lymphoma in the third-line setting and ALCL in the second-line setting.

Michelle A. Fanale, MD, Associate Professor, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of brentuximab vedotin as frontline treatment of systemic anaplastic large cell lymphoma (ALCL).

In the phase II trial, patients with low-risk factors saw a 70% to 80% chance of being in remission for five years, compared to 15% to 20% of patients with higher risk factors. In the phase III trial, Fanale says, researchers look to compare CHOP chemotherapy to brentuximab vedotin + CHP in the frontline treatment of mature T-cell lymphomas and to enroll patients with high-risk disease. The goal remains to improve outcomes for high-risk patients by escalating chemotherapy or adding a targeted therapy.

Brentuximab vedotin is currently approved for Hodgkin lymphoma in the third-line setting and ALCL in the second-line setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x